Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $231.44, for a total transaction of $694,320.00. Following the sale, the insider directly owned 139,486 shares of the company’s stock, valued at $32,282,639.84. This represents a 2.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, February 3rd, Solomon Moshkevich sold 1,639 shares of Natera stock. The shares were sold at an average price of $230.77, for a total transaction of $378,232.03.
• On Wednesday, January 28th, Solomon Moshkevich sold 1,200 shares of Natera stock. The stock was sold at an average price of $237.66, for a total transaction of $285,192.00.
• On Tuesday, January 27th, Solomon Moshkevich sold 1,013 shares of Natera stock. The stock was sold at an average price of $240.53, for a total transaction of $243,656.89.
• On Wednesday, January 21st, Solomon Moshkevich sold 293 shares of Natera stock. The shares were sold at an average price of $235.00, for a total transaction of $68,855.00.
• On Tuesday, January 20th, Solomon Moshkevich sold 23,205 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70.
• On Friday, January 2nd, Solomon Moshkevich sold 2,951 shares of Natera stock. The stock was sold at an average price of $228.95, for a total value of $675,631.45.
• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $238.15, for a total value of $714,450.00.

Natera Stock Performance

Shares of NTRA stock opened at $197.08 on Friday. The company has a market cap of $27.26 billion, a P/E ratio of -86.06 and a beta of 1.64. The stock has a 50 day simple moving average of $234.15 and a two-hundred day simple moving average of $195.75. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera’s quarterly revenue was up 34.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) earnings per share. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Regulatory/catalyst: Natera submitted a PMA to the FDA for Signatera CDx to detect minimal residual disease in bladder cancer after positive phase‑3 results — a potential pathway to a companion‑diagnostic revenue stream and better reimbursement/clinical adoption if approved. Natera files Signatera CDx PMA (Zacks)
• Neutral Sentiment: Routine insider trims: Several non‑executive insiders (e.g., Solomon Moshkevich, John Fesko) sold modest, single‑digit percentages of their positions; these look like routine liquidity actions but add incremental supply. InsiderTrades report on recent sales
• Negative Sentiment: Material CEO sale: CEO Steven Chapman sold 85,299 shares (~40% reduction) on Feb 2 for roughly $19.7M — a large, high‑visibility block that investors commonly view as a negative signal and that likely amplified downward pressure. CEO Form 4 (SEC)
• Negative Sentiment: Additional executive selling: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), further trimming insider ownership and reinforcing near‑term selling pressure. CEO additional Form 4 CFO Form 4 (SEC)

Analyst Ratings Changes

Several equities research analysts have weighed in on NTRA shares. Stephens lifted their price target on shares of Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a research note on Monday, January 12th. BTIG Research upped their price target on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Finally, JPMorgan Chase & Co. boosted their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in the stock. Flagship Harbor Advisors LLC purchased a new stake in shares of Natera in the fourth quarter worth approximately $41,000. Hilltop National Bank purchased a new position in shares of Natera during the second quarter valued at approximately $33,000. Horizon Investments LLC bought a new stake in Natera during the third quarter worth $32,000. Sound Income Strategies LLC raised its position in Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after buying an additional 110 shares during the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in Natera during the 4th quarter valued at $62,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.